Cornerstone raises funds for pancreatic cancer candidate
This article was originally published in Scrip
Executive Summary
Cornerstone Pharmaceuticals has raised $6.2 million from private investors to fund trials of its lead anticancer molecule, CPI-613. The series B-4 investment was led by Althea Partners.